Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Allisartan Isoproxil/Indapamide SR in Uncontrolled Essential Hypertension
NCT06500689Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of allisartan isoproxil, indapamide in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Dec 2021; status: completed.
02
Drugs
allisartan isoproxilindapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06500689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500689.